Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Mesoblast Limited (MESO) Chart:

MESO chart by TradingView

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-1710CALL0 01298.65TRUE00
2025-04-1720CALL0 0880.18TRUE00
2025-04-1730CALL0 0667.25TRUE00
2025-04-1747.8CALL0 0486.57TRUE00
2025-04-17512.2CALL0 0517.75TRUE00
2025-04-17611.4CALL0 2384.31TRUE00
2025-04-1779.1CALL0 0175.33TRUE00
2025-04-1787.4CALL0 325621.78TRUE00
2025-04-1791.13CALL0 62228.96TRUE00
2025-04-17101.12CALL0 36158.9TRUE00
2025-04-17110.38CALL0 37192.37FALSE00
2025-04-17120.45CALL0 82119.67FALSE00
2025-04-17130.2CALL5 256156.76FALSE00
2025-04-17140.15CALL0 96260.82FALSE00
2025-04-17150.2CALL5 1449216.33FALSE0.20
2025-04-17160.1CALL0 56320.92FALSE00
2025-04-17170.15CALL0 117245.84FALSE00
2025-04-17180.3CALL0 405748FALSE00
2025-04-17190.24CALL0 265772.66FALSE00
2025-04-17200.1CALL0 1242339.6FALSE00
2025-04-17212.3CALL0 39816.72FALSE00
2025-04-17220.7CALL0 14836.57FALSE00
2025-04-17231.7CALL0 6633.39FALSE00
2025-04-17240.15CALL0 12872.73FALSE00
2025-04-17250.35CALL0 7889.29FALSE00
2025-04-17260.3CALL0 10904.97FALSE00
2025-04-17270.2CALL0 1919.86FALSE00
2025-04-17280CALL0 0934.04FALSE00
2025-04-17290CALL0 0947.55FALSE00
2025-04-17301.5CALL0 400960.47FALSE00
2025-04-17310.45CALL0 1972.83FALSE00
2025-04-17321.5CALL0 1984.68FALSE00
2025-04-17331.4CALL0 6996.06FALSE00
2025-04-17341.25CALL0 11007FALSE00
2025-04-17351.45CALL0 21017.54FALSE00
2025-04-1710PUT0 00FALSE00
2025-04-1720PUT0 00FALSE00
2025-04-1730PUT0 00FALSE00
2025-04-1740PUT0 00FALSE00
2025-04-1750.65PUT0 5701321.11FALSE00
2025-04-1761.1PUT0 201076.93FALSE00
2025-04-1770.8PUT0 16409.16FALSE00
2025-04-1781PUT0 502275.33FALSE00
2025-04-1790.35PUT0 132114.76FALSE00
2025-04-17100.7PUT0 675266.92FALSE00
2025-04-17110.9PUT0 21209.17TRUE00
2025-04-17122.69PUT0 29248TRUE00
2025-04-17132.01PUT0 81205.63TRUE00
2025-04-17143.7PUT0 82235.29TRUE00
2025-04-17155.3PUT0 438160.73TRUE00
2025-04-17162.1PUT0 7606.74TRUE00
2025-04-17176PUT0 15414.49TRUE00
2025-04-17188.75PUT0 574248.43TRUE00
2025-04-17196.55PUT0 2308.12TRUE00
2025-04-172010.5PUT0 371283.27TRUE00
2025-04-172110.3PUT0 3731.53TRUE00
2025-04-17226.4PUT0 16281.32TRUE00
2025-04-17230PUT0 0352.87TRUE00
2025-04-172410.6PUT0 0388.06TRUE00
2025-04-17257PUT0 1839.53TRUE00
2025-04-17260PUT0 0819.66TRUE00
2025-04-17270PUT0 0426.31TRUE00
2025-04-17289.5PUT0 1387.77TRUE00
2025-04-17290PUT0 0398.22TRUE00
2025-04-17300PUT0 0408.24TRUE00
2025-04-17310PUT0 0417.87TRUE00
2025-04-17320PUT0 0899.34TRUE00
2025-04-17330PUT0 0910.73TRUE00
2025-04-17340PUT0 00TRUE00
2025-04-17350PUT0 0950.33TRUE00
2025-05-1650CALL0 0122.14TRUE00
2025-05-1660CALL0 0430.99TRUE00
2025-05-1670CALL0 0113.13TRUE00
2025-05-1680CALL0 0109.65TRUE00
2025-05-1692.5CALL0 199.15TRUE00
2025-05-16100CALL0 0123.8TRUE00
2025-05-16111.75CALL0 1140.47FALSE00
2025-05-16121.62CALL0 4148.52FALSE00
2025-05-16130.55CALL0 10100.46FALSE00
2025-05-16140.6CALL0 2181.44FALSE00
2025-05-16150.65CALL0 5146.97FALSE00
2025-05-16160CALL0 0188.44FALSE00
2025-05-16170CALL0 0196.48FALSE00
2025-05-16180CALL0 0205.45FALSE00
2025-05-16190.35CALL0 1297.57FALSE00
2025-05-16200CALL0 0350.1FALSE00
2025-05-16250CALL0 0391.52FALSE00
2025-05-1650PUT0 0584.44FALSE00
2025-05-1660PUT0 0268.86FALSE00
2025-05-1670PUT0 0220.54FALSE00
2025-05-1680PUT0 0193.31FALSE00
2025-05-1690.94PUT0 12118.71FALSE00
2025-05-16101.3PUT0 13129.03FALSE00
2025-05-16111.95PUT0 384.18TRUE00
2025-05-16122.7PUT0 6150.1TRUE00
2025-05-16132.47PUT0 2078.63TRUE00
2025-05-16142.1PUT0 1499.14TRUE00
2025-05-16150PUT0 0168.81TRUE00
2025-05-16163.56PUT0 1118.89TRUE00
2025-05-16170PUT0 0135.93TRUE00
2025-05-16180PUT0 0132.73TRUE00
2025-05-16190PUT0 0124.69TRUE00
2025-05-162010.37PUT0 33132.6TRUE00
2025-05-16250PUT0 0374.76TRUE00
2025-07-18315CALL0 0523.09TRUE00
2025-07-18512.3CALL0 12126.13TRUE00
2025-07-1860CALL0 093.43TRUE00
2025-07-18710.8CALL0 5094.52TRUE00
2025-07-1885.75CALL0 5132.48TRUE00
2025-07-1893.24CALL0 4696.19TRUE00
2025-07-18102.71CALL0 51697.49TRUE00
2025-07-18113CALL0 4255.5FALSE00
2025-07-18121.55CALL18 79096.45FALSE-0.15-0.09
2025-07-18131.4CALL0 15672.37FALSE00
2025-07-18140.82CALL0 8670.78FALSE00
2025-07-18150.85CALL0 262094.31FALSE00
2025-07-18160.7CALL0 117479.42FALSE00
2025-07-18170.6CALL0 10182.75FALSE00
2025-07-18180.62CALL0 17085.11FALSE00
2025-07-18190.45CALL11 50699.61FALSE0.450
2025-07-18200.38CALL62 431999.83FALSE0.030.09
2025-07-18210.55CALL0 1896.09FALSE00
2025-07-18220.43CALL0 81104.71FALSE00
2025-07-18231.4CALL0 108102.13FALSE00
2025-07-18240.2CALL147 5141100.78FALSE-0.05-0.2
2025-07-18251.16CALL0 9109.5FALSE00
2025-07-18260.7CALL0 7147.37FALSE00
2025-07-18270.14CALL0 155123.27FALSE00
2025-07-18282CALL0 1247.26FALSE00
2025-07-18290CALL0 0250.86FALSE00
2025-07-18300.2CALL0 45254.31FALSE00
2025-07-18311.73CALL0 1257.61FALSE00
2025-07-18320.2CALL0 8260.77FALSE00
2025-07-18331.4CALL0 4263.8FALSE00
2025-07-18341.3CALL0 2266.72FALSE00
2025-07-18350.55CALL0 2269.53FALSE00
2025-07-1830PUT0 0405.66FALSE00
2025-07-1851.05PUT0 2170.32FALSE00
2025-07-1861.1PUT0 8126.48FALSE00
2025-07-1870.55PUT0 9116.14FALSE00
2025-07-1880.75PUT0 0137.77FALSE00
2025-07-1891.12PUT0 1278.4FALSE00
2025-07-18102.21PUT0 7366.03FALSE00
2025-07-18112.2PUT0 590.98TRUE00
2025-07-18122.55PUT0 12102.06TRUE00
2025-07-18134.2PUT20 51101.17TRUE4.20
2025-07-18144.9PUT8 40114.74TRUE-0.5-0.09
2025-07-18156PUT0 112497.46TRUE00
2025-07-18164.34PUT0 41100.56TRUE00
2025-07-18176PUT0 19105.33TRUE00
2025-07-18188.7PUT0 589106.27TRUE00
2025-07-18190PUT0 0121.49TRUE00
2025-07-182010.57PUT0 33104.79TRUE00
2025-07-18216.01PUT0 10130.01TRUE00
2025-07-18220PUT0 0114.94TRUE00
2025-07-18230PUT0 0119.59TRUE00
2025-07-18240PUT0 0124TRUE00
2025-07-18259PUT0 3124.06TRUE00
2025-07-18260PUT0 0235.86TRUE00
2025-07-18270PUT0 00TRUE00
2025-07-18280PUT0 0112.33TRUE00
2025-07-18290PUT0 0115.58TRUE00
2025-07-18300PUT0 0251.87TRUE00
2025-07-18310PUT0 00TRUE00
2025-07-18320PUT0 0258.92TRUE00
2025-07-18330PUT0 0262.26TRUE00
2025-07-18340PUT0 00TRUE00
2025-07-18350PUT0 0277.98TRUE00
2025-10-1730CALL0 091.04TRUE00
2025-10-1756.2CALL0 5992.16TRUE00
2025-10-1760CALL0 0137.41TRUE00
2025-10-1770CALL0 086.71TRUE00
2025-10-1786.1CALL0 274.67TRUE00
2025-10-1796.45CALL0 352.58TRUE00
2025-10-17102.55CALL0 50987.75TRUE00
2025-10-17113.45CALL0 783.44FALSE00
2025-10-17122.25CALL100 176991.89FALSE0.420.23
2025-10-17132CALL0 5859.95FALSE00
2025-10-17141.7CALL1 1390.74FALSE1.70
2025-10-17151.75CALL0 19166.22FALSE00
2025-10-17161.05CALL0 50086.74FALSE00
2025-10-17171.9CALL0 377.34FALSE00
2025-10-17183.9CALL0 5071.66FALSE00
2025-10-17191.58CALL0 1377.01FALSE00
2025-10-17200.8CALL0 177589.6FALSE00
2025-10-17210.7CALL25 090.18FALSE0.70
2025-10-17221.25CALL0 876.37FALSE00
2025-10-17232.25CALL0 20082.24FALSE00
2025-10-17250.97CALL0 383.41FALSE00
2025-10-17300.49CALL0 2115.44FALSE00
2025-10-1730PUT0 0476.72FALSE00
2025-10-1750PUT0 0155.18FALSE00
2025-10-1760.91PUT0 2597.35FALSE00
2025-10-1770PUT0 0104.66FALSE00
2025-10-1781.8PUT0 2574.1FALSE00
2025-10-1791.6PUT0 274.68FALSE00
2025-10-17102.72PUT0 21698.46FALSE00
2025-10-17112.6PUT0 396.71TRUE00
2025-10-17123.95PUT0 176197.7TRUE00
2025-10-17133.2PUT0 6697.27TRUE00
2025-10-17145PUT0 16102.35TRUE00
2025-10-17156.7PUT0 20596.28TRUE00
2025-10-17160PUT0 0118.2TRUE00
2025-10-17170PUT0 091.17TRUE00
2025-10-17180PUT0 088.9TRUE00
2025-10-17197.86PUT0 093.8TRUE00
2025-10-17200PUT0 094.21TRUE00
2025-10-17210PUT0 094.01TRUE00
2025-10-17220PUT0 082.45TRUE00
2025-10-17230PUT0 082.6TRUE00
2025-10-17250PUT0 080.27TRUE00
2025-10-17300PUT0 098.78TRUE00
2026-01-160.51CALL15 160TRUE00
2026-01-1610CALL0 00TRUE00
2026-01-161.50CALL0 00TRUE00
2026-01-1621.67CALL30 4600TRUE00
2026-01-162.50.5CALL148 26090TRUE00
2026-01-1631CALL0 50TRUE00
2026-01-1640CALL0 00TRUE00
2026-01-1651.4CALL30 4610TRUE00
2026-01-160.50PUT0 00FALSE00
2026-01-1610PUT0 00FALSE00
2026-01-161.50PUT0 00FALSE00
2026-01-1620PUT0 00FALSE00
2026-01-162.50PUT0 00FALSE00
2026-01-1630PUT0 00FALSE00
2026-01-1640PUT0 00FALSE00
2026-01-1650PUT0 00FALSE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm